MIPSS70 scoring
Current understanding
Mutation-Enhanced International Prognostic Scoring System for transplant-age myelofibrosis patients (age ≤ 70). Includes high-molecular-risk mutations.
Evidence log
Open questions
Related
Contributing findings
Unmasking Additional Mutations: A Single Institution Study in Myeloproliferative Neoplasms.
31-jul-2026
novelty 3
per-area 2
strengthens
Precision medicine in myelofibrosis: from molecular profiling to personalized therapy.
15-jul-2026
novelty 2
per-area 2
mentions
Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation.
13-jul-2026
novelty 2
per-area 2
mentions
Caris Chromoseq Data Collection
02-jul-2026
novelty 2
per-area 2
mentions
[Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)].
17-jun-2026
novelty 2
per-area 2
strengthens
Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.
06-jun-2026
novelty 3
per-area 1
mentions
Calreticulin mutations in essential thrombocythemia and primary myelofibrosis.
01-jun-2026
novelty 2
per-area 1
mentions
Clonal Architecture of ASXL1-mutated Myelofibrosis
09-mar-2026
novelty 3
per-area 2
mentions